Genetic studies suggest that ezetimibe, bempedoic acid and the PCSK9 inhibitors reduce the risk of ASCVD similar to statins when compared to an equivalent degree of LDL cholesterol reduction. Here, PCSK9 is linked to atherosclerosis.